Acquisition lifted revenue 61.2% but continuing NPAT fell 51.8%

Management attributes the gap directly to the direct and indirect cost of acquiring and consolidating the new GP practices, and notes that underlying organic revenue grew 16.7% to $2.8m. That means roughly $1.7m of the $1.7m year-on-year revenue increase came from acquired practices rather than the existing base.

Operating cash flow stepped down to $0.3m from $0.4m in the prior comparable period. Cash on hand fell to $0.9m from $1.8m, and the group now carries a $0.6m bank loan, leaving a small net cash position of about $0.3m. The board has declared an interim dividend of 2.4 cps.

Both reporting segments saw results compress: aged medical care services contributed $0.4m of segment result against $0.8m a year earlier, and general practice services delivered $0.1m against $0.2m. Aged care also grew to 88% of revenue from 81%, which means the prior comparison no longer provides a reliable basis for assessing the current mix. This matters because the acquisition thesis only works if integrated practices lift group earnings, and at this point they are doing the opposite.

Balance-sheet flexibility has narrowed. Cash dropped by roughly $0.9m and gross borrowings of $0.6m appeared on the balance sheet for the first time. The change is small in dollars but meaningful for a company of this size, because it leaves less buffer to fund any further bolt-ons without raising equity or stretching debt.

Return on equity halved. ROE fell to 12.3% from 29.6%, reflecting both the higher equity base and the lower earnings. The implication is that capital deployed into acquisitions has not yet earned its prior return profile, and the burden of proof now sits on second-half integration.

The prior-year split (HY22 was 27.6% of FY22 NPAT) suggests the second half is normally the heavier earnings half for this business, so a step-up in 2H23 would be in line with seasonality rather than evidence of integration success. The release does not commit to a timeframe over which acquisition costs are expected to roll off, which is the single most important piece of forward information missing for this result.

There are no disclosed one-off items, no discontinued operations, and the effective tax rate (30.3% versus 28.0%) is close to the New Zealand statutory rate, so PBT and NPAT tell the same story. EBITDA-to-OCF conversion of 42.6% is modest and weaker than the comparable period in dollar terms, partly because trade receivables are still being absorbed from the new practices; receivable days actually improved to 17.5 from 24.4, which suggests the cash drag is integration-related rather than collections-related.

Capital allocation looks stretched against the new earnings base. The interim dividend implies a payout of 75.1% of continuing NPAT and 145% of free cash flow before lease payments. That coverage holds for this half, but only because capex was minimal at 0.4% of revenue. If acquisition-related cash needs persist into the second half, the dividend, the cash buffer, and the small loan balance start to compete for the same headroom.

This briefing cannot assess the size, timing, or recoverability of specific acquisition and integration costs because the release does not separate them from underlying operating expense.